|Bid||91.20 x 1100|
|Ask||91.21 x 800|
|Day's Range||90.64 - 91.50|
|52 Week Range||76.41 - 91.50|
|PE Ratio (TTM)||40.21|
|Earnings Date||Aug 21, 2018|
|Forward Dividend & Yield||2.00 (2.26%)|
|1y Target Est||95.40|
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.
Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It now expects adjusted EPS of $2–$2.15 compared to the previous estimate of $2.55–$2.65. The decrease represents Dentsply’s expectation of a decline in revenue for the remainder of 2018, driven by higher levels of inventory destocking at its dealer partners.
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%. In this series, we’ll explore its financial performance, how its segments are performing, its recent acquisitions, its valuation metrics, and what analysts expect in the coming months. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies.
After more than six months since its last high, the S&P 500 is back on the road to records. "We think the S&P is going to breakthrough that January resistance. You want to own stocks," Ari Wald, head of technical analysis at Oppenheimer, told CNBC's " Trading Nation " on Tuesday.
When her daughter, Sydney, was diagnosed with Type 1 diabetes at age 8, Kate Farnsworth stopped sleeping through the night. At 6 a.m., another alarm went off to signal the next insulin dose, but by then, Kate had usually snapped awake again already. When Sydney got home from school each afternoon, Kate was there to check her glucose level.
Mazor Robotics (NASDAQ:MZOR) fell nearly 15 percent last week after the company reported second-quarter results. Mazor Robotics reported revenue of $13.2 million as customers adopted its technologies in robotic guidance systems. At 20 times sales, MZOR stock is not cheap.
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.
Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.
IntriCon Corporation (NASDAQ:IIN) is a small company with big promise. Granted, its market cap is less than $500 million, so now that investors see the growth potential, the stock is getting a lot of attention from mutual funds, institutional investors and momentum traders.
System placements grew 25%, but lower pricing terms from its commercial deal with Medtronic cause the top line to head in reverse.
On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
August 1, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced Paurvi Bhatt as the new President of the Medtronic Foundation and Vice President of Medtronic Philanthropy. Effective immediately, Bhatt will oversee all Medtronic Foundation and Medtronic Philanthropy operations, which aim to expand access to healthcare in underserved communities around the world and support healthy communities where Medtronic`s 86,000 employees live and give. Bhatt succeeds Dr. Jacob Gayle in this leadership role, following Dr. Gayle`s transition to his new position as Vice President of Social Impact for Medtronic.
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
Intellis™, the Next Generation Medtronic Spinal Cord Stimulator for Long-Term Management of Chronic Pain, Now Licensed in Canada
Twenty Runners Representing 13 Countries to Participate in the Medtronic Twin Cities Marathon Weekend This October DUBLIN - July 31, 2018 - This October, 20 runners from 13 different countries around the ...
DaVita (DVA), which divides its business into two segments, DaVita Kidney Care and DaVita Medical Group, is set to release its Q2 2018 results tomorrow. Analysts expect it to post EPS of $0.97 on revenue of $2.8 billion. The chart below shows DaVita’s EPS and revenue since Q1 2017, as well as analysts’ Q2 2018 estimates.